Research programme: next generation alpha4beta7 integrin inhibitors - Eli Lilly and Company
Latest Information Update: 22 Aug 2024
At a glance
- Originator Morphic Therapeutic
- Developer Eli Lilly and Company
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Alpha4beta7 integrin antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gastrointestinal disorders
Most Recent Events
- 16 Aug 2024 Morphic Therapeutic has been acquired and merged into Eli Lilly and Company
- 28 Feb 2023 Preclinical trials in Gastrointestinal disorders in USA (PO) (Morphic Therapeutic pipeline, February 2023)